Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial-Reference-Cited by-同舟云学术

Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial

Published:2017-12 Issue:10111 Volume:390 Page:2461-2471
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Kang Yoon-Koo,Boku Narikazu,Satoh Taroh,Ryu Min-Hee,Chao Yee,Kato Ken,Chung Hyun Cheol,Chen Jen-Shi,Muro Kei,Kang Won Ki,Yeh Kun-Huei,Yoshikawa Takaki,Oh Sang Cheul,Bai Li-Yuan,Tamura Takao,Lee Keun-Wook,Hamamoto Yasuo,Kim Jong Gwang,Chin Keisho,Oh Do-Youn,Minashi Keiko,Cho Jae Yong,Tsuda Masahiro,Chen Li-Tzong

Publisher

Elsevier BV

Subject

General Medicine

Reference32 articles.

1. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012;Ferlay;Int J Cancer,2015

2. Disparities in gastric cancer chemotherapy between the East and West;Ohtsu;J Clin Oncol,2006

3. Screening of gastric cancer in Asia;Sugano;Best Pract Res Clin Gastroenterol,2015

4. Gastric cancer, version 3. 2016, NCCN Clinical Pratice Guidelines in Oncology;Ajani;J Natl Compr Canc Netw,2016

5. Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment, and follow-up;Smyth;Ann Oncol,2016

Cited by 1802 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Uncovering the potential of APOD as a biomarker in gastric cancer: A retrospective and multi-center study;Computational and Structural Biotechnology Journal;2024-12

2. Identifying and validating angiogenesis-related genes remodeling tumor microenvironment and suppressing immunotherapy response in gastric cancer;Gene;2024-11

3. A novel 7-phenoxy-benzimidazole derivative as a potent and orally available BRD4 inhibitor for the treatment of melanoma;Bioorganic & Medicinal Chemistry;2024-10

4. Identification of microenvironment features associated with primary resistance to anti-PD-1/PD-L1 + antiangiogenesis in gastric cancer through spatial transcriptomics and plasma proteomics;Molecular Cancer;2024-09-13

5. A Case Report of Long-Term Survival Achieved by Nivolumab and Hyperthermia With Multiple Local Therapies for the Peritoneal Dissemination of Gastric Cancer;Cureus;2024-09-11